SYNGAP1-related disorder (S1RD): Requests research proposals to advance research that supports therapeutic development for S1RD. **One $74,851 grant available** for projects addressing any stage of pre-clinical to clinical development with a priority in an endpoint proteomics biomarker is desired. Areas of priority interest include, but are not limited to:

1. Development of clinical trial readiness, including identification of novel biomarkers and non-seizure clinical endpoints.
2. Understanding pathomechanisms and genotype-phenotype relationships of SYNGAP1 disorders, with an emphasis in missense variant structure-function analysis.
3. Developing or advancing therapeutic approaches to correct SYNGAP1 disorders, including the repurposing of FDA-approved drugs.
4. Determining the trajectory of SYNGAP1 disorders from pediatric to adult presentations.